Skip to content

Study · Non-randomized trial · n = 8 · 1989

2 results

Use of continuous subcutaneous growth hormone-releasing hormone (GHRH (1-29)NH2) infusions to augment growth hormone secretion and to promote growth.

Brain C, Hindmarsh PC, Pringle PJ, Brook CG

Acta paediatrica Scandinavica. Supplement1 Jan 1989Cited by 3 (Europe PMC)

PMID2546369 (opens in a new tab)DOI10.1111/j.1651-2227.1989.tb17180.x (opens in a new tab)PepBankPUB-02546369
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children aged 6-9 years with partial GH insufficiency, continuous subcutaneous GHRH(1-29)NH2 augmented GH secretion in all children after 3 and 6 months.

    In plain wordsIn children with partial growth hormone shortage, continuous GHRH infusion increased growth hormone release in all eight children, with no control group.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH secretion
    Study

    n = 8

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous infusion · 3 and 6 monthsAs given in this study (human).

    Source sentences

    Summary
    All the children showed augmentation of GH secretion
    1 context sentence
    Summary · context
    The present report details the results of treatment with continuous subcutaneous infusions of GHRH (1-29)NH2 in eight children aged 6-9 years with partial GH insufficiency.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children aged 6-9 years with partial GH insufficiency, continuous subcutaneous GHRH(1-29)NH2 increased growth velocity in all children after 3 and 6 months.

    In plain wordsIn children with partial growth hormone shortage, continuous GHRH infusion raised growth speed in all eight children, with no control group.

    Peptide
    Sermorelin
    Outcome
    IncreaseGrowth velocity
    Study

    n = 8

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous infusion · 3 and 6 monthsAs given in this study (human).

    Source sentences

    Summary
    an increase in growth velocity after 3 and 6 months of therapy.
    1 context sentence
    Summary · context
    The present report details the results of treatment with continuous subcutaneous infusions of GHRH (1-29)NH2 in eight children aged 6-9 years with partial GH insufficiency.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.